Aktuellt
SENASTE
Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to focus entirely on its Catalyst product. With the SEK150m (before transaction costs) now also raised in a direct share issue, we believe it has a good chance of reaching a positive cash flow on the existing cash position. We will return with an update shortly, presenting our new financial estimates and fair value range. On the back of the news, we expect the share to react positively today, around 10% up.
LÄS MER
